• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

普拉曲沙治疗两名日本蕈样肉芽肿难治性患者。

Pralatrexate for refractory mycosis fungoides in two Japanese patients.

作者信息

Teraishi Mika, Oguro Tokuko, Kusume Ema, Kobashi Haruka, Sano Hozumi, Fujioka Ai, Yamamoto Mayuko, Nakajima Hideki, Sano Shigetoshi

机构信息

Department of Dermatology, Kochi Medical School, Kochi University, Kochi, Japan.

出版信息

J Dermatol. 2021 May;48(5):667-671. doi: 10.1111/1346-8138.15761. Epub 2021 Jan 16.

DOI:10.1111/1346-8138.15761
PMID:33454985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8248132/
Abstract

Pralatrexate has been approved for the treatment of relapsed/refractory peripheral T cell lymphomas. Studies in the U.S. also support the clinical efficacy of pralatrexate to treat advanced-stage cutaneous T-cell lymphomas, but outcomes in Japanese patients have not yet been reported. We herein describe two Japanese patients with heavily-pretreated relapsed/refractory mycosis fungoides that were successfully controlled by pralatrexate.

摘要

普拉曲沙已被批准用于治疗复发/难治性外周T细胞淋巴瘤。美国的研究也支持普拉曲沙治疗晚期皮肤T细胞淋巴瘤的临床疗效，但日本患者的治疗结果尚未见报道。我们在此描述了两名日本蕈样肉芽肿复发/难治患者，他们经过大量预处理后，使用普拉曲沙成功得到控制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee98/8248132/51773bb1b613/JDE-48-667-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee98/8248132/f59f0dabfcf3/JDE-48-667-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee98/8248132/51773bb1b613/JDE-48-667-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee98/8248132/f59f0dabfcf3/JDE-48-667-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee98/8248132/51773bb1b613/JDE-48-667-g002.jpg

相似文献

1
Pralatrexate for refractory mycosis fungoides in two Japanese patients.普拉曲沙治疗两名日本蕈样肉芽肿难治性患者。
J Dermatol. 2021 May;48(5):667-671. doi: 10.1111/1346-8138.15761. Epub 2021 Jan 16.
2
Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.普拉曲沙单药或联合贝沙罗汀：复发/难治性蕈样肉芽肿的长期耐受性
Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):297-304. doi: 10.1016/j.clml.2014.01.010. Epub 2014 Feb 4.
3
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.普拉曲沙治疗复发/难治性转化型蕈样真菌病有效：来自 PROPEL 研究的亚组疗效分析。
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. doi: 10.1016/j.clml.2012.01.010. Epub 2012 Apr 26.
4
Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation.大细胞转化的四期红皮病蕈样肉芽肿经普拉曲沙和罗米地辛联合治疗达到完全缓解，随后行异基因造血干细胞移植。
Australas J Dermatol. 2021 Aug;62(3):e400-e403. doi: 10.1111/ajd.13606. Epub 2021 May 24.
5
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.普拉曲沙用于日本复发或难治性外周T细胞淋巴瘤患者的I/II期研究。
Cancer Sci. 2017 Oct;108(10):2061-2068. doi: 10.1111/cas.13340. Epub 2017 Sep 4.
6
Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.与单药吉西他滨或普拉曲沙相比，阿仑单抗是难治性 Sézary 综合征有效的三线治疗方案：一项系统评价。
Eur J Dermatol. 2018 Dec 1;28(6):764-774. doi: 10.1684/ejd.2018.3444.
7
Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.普拉曲沙作为一线化疗难治的晚期结外鼻型自然杀伤/T细胞淋巴瘤患者异基因造血干细胞移植的桥梁：一例报告
J Med Case Rep. 2020 Mar 17;14(1):43. doi: 10.1186/s13256-020-02363-3.
8
Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.普拉曲沙注射液治疗复发或难治性外周 T 细胞淋巴瘤。
Expert Rev Hematol. 2020 Jun;13(6):577-583. doi: 10.1080/17474086.2020.1756257. Epub 2020 Apr 26.
9
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.鉴定复发或难治性皮肤 T 细胞淋巴瘤患者中普拉曲沙的有效且耐受性良好的剂量。
Blood. 2012 May 3;119(18):4115-22. doi: 10.1182/blood-2011-11-390211. Epub 2012 Mar 6.
10
Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.普拉曲沙对一名有自体干细胞移植史的复发/难治性外周T细胞淋巴瘤患者诱导出持久缓解：1例接受普拉曲沙治疗3年以上患者的病例报告
Medicine (Baltimore). 2019 Jul;98(30):e16482. doi: 10.1097/MD.0000000000016482.

本文引用的文献

1
Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin.普拉曲沙联合亚叶酸钙预防性给药用于难治性外周T细胞淋巴瘤（未另行分类）的长期治疗
Case Rep Oncol. 2019 Jul 16;12(2):529-536. doi: 10.1159/000501070. eCollection 2019 May-Aug.
2
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate.普拉曲沙不同剂量治疗皮肤T细胞淋巴瘤患者的临床活性
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e445-e447. doi: 10.1016/j.clml.2018.06.020. Epub 2018 Jun 27.
3
Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
晚期蕈样霉菌病和赛泽里综合征的系统性治疗选择。
Curr Oncol Rep. 2018 Mar 23;20(4):32. doi: 10.1007/s11912-018-0678-x.
4
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.一项罗米地辛联合培美曲塞治疗复发难治性 T 细胞淋巴瘤的 I 期临床研究显示出显著的疗效。
Blood. 2018 Jan 25;131(4):397-407. doi: 10.1182/blood-2017-09-806737. Epub 2017 Nov 15.
5
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.普拉曲沙用于日本复发或难治性外周T细胞淋巴瘤患者的I/II期研究。
Cancer Sci. 2017 Oct;108(10):2061-2068. doi: 10.1111/cas.13340. Epub 2017 Sep 4.
6
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.普拉曲沙联合口服贝沙罗汀治疗复发/难治性皮肤 T 细胞淋巴瘤的 I/II 期开放标签、剂量发现研究结果。
Clin Cancer Res. 2017 Jul 15;23(14):3552-3556. doi: 10.1158/1078-0432.CCR-16-2064. Epub 2017 Feb 6.
7
Methotrexate and Pralatrexate.甲氨蝶呤和普拉曲沙。
Dermatol Clin. 2015 Oct;33(4):747-55. doi: 10.1016/j.det.2015.05.009. Epub 2015 Aug 1.
8
Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.普拉曲沙单药或联合贝沙罗汀：复发/难治性蕈样肉芽肿的长期耐受性
Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):297-304. doi: 10.1016/j.clml.2014.01.010. Epub 2014 Feb 4.
9
Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group.《皮肤淋巴瘤治疗指南（2011）》：日本皮肤癌学会 - 淋巴瘤研究组的共识声明。
J Dermatol. 2013 Jan;40(1):2-14. doi: 10.1111/j.1346-8138.2012.01639.x. Epub 2012 Aug 20.
10
Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.普拉曲沙治疗复发/难治性转化型蕈样真菌病有效：来自 PROPEL 研究的亚组疗效分析。
Clin Lymphoma Myeloma Leuk. 2012 Aug;12(4):238-43. doi: 10.1016/j.clml.2012.01.010. Epub 2012 Apr 26.